Veronica Ramirez
Primary Care · Sacramento, CANPI 1801199260
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,873 of the $82,859 with a category attached, or 77.1%. Gilead accounts for 98.2% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $32,464, 4.3 times the $7,575 reported in 2021. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $366.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$81K
- Viiv Healthcare Company$981
- Merck$192
- Janssen Scientific Affairs, LLC$115
- Johnson & Johnson$71
- Janssen Products, LP$65
- plus $64 from 2 others
What the payments were for
- Consulting fees$4100%
- Speaking & faculty fees$63,87377%
- Travel & lodging$11,67514%
- Food & beverage$6,8088%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 184 | $81,372 |
| Viiv Healthcare Company | 27 | $981 |
| Merck | 7 | $192 |
| Janssen Scientific Affairs, LLC | 2 | $115 |
| Johnson & Johnson(2 entities) | 3 | $71 |
| Janssen Products, LP | 1 | $65 |
| EMD Serono, Inc. | 1 | $35 |
| Organon | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$82,859 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 270 | $1,033,254 |
| JulucaDolutegravir/Rilpivirine | 85 | $264,954 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 66 | $252,742 |
| TivicayDolutegravir Sodium | 65 | $151,869 |
| DescovyEmtricitabine/Tenofov Alafenam | 52 | $114,933 |
| DovatoDolutegravir Sodium/Lamivudine | 36 | $97,518 |
| PrezcobixDarunavir/Cobicistat | 35 | $80,241 |
| Egrifta SvTesamorelin Acetate | 11 | $77,875 |
| CabenuvaCabotegravir/Rilpivirine | 11 | $73,915 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 15 | $48,924 |
| OzempicSemaglutide | 45 | $45,461 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $40,511 |
| XifaxanRifaximin | 12 | $34,090 |
| PrezistaDarunavir | 19 | $33,393 |
| TrulicityDulaglutide | 24 | $20,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $81,372 | $1,197,111337 claims |
| Viiv Healthcare CompanyJuluca, Triumeq, Tivicay, Dovato, Cabenuva | $981 | $840,998263 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $71 | $87,49948 claims |
| Janssen Scientific Affairs, LLCPrezista | $115 | $33,39319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.
Other primary care in Sacramento
- Rolando SantosSacramento$9K
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
- Lynda TranHuntington Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.